Keywords: teva, says, azilect, slows, progression, pd, israeli

Teva says Azilect slows progression of PD

Article | 23 June 2008

Print This

Israeli drug major Teva Pharmaceuticals Industries says that a Phase III study of Azilect (rasagiline) met its primary endpoints and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in